

KynderMed Announces Publication of Favorable Harvard Clinical Study Results

PRESS RELEASE PR Newswire

Mar. 27, 2019, 12:00 AM

ST. PETERSBURG, Fla., March 27, 2019 /PRNewswire-PRWeb/
-- KynderMed, Inc. announces that a recently concluded NIH-funded clinical study conducted at Harvard's Brigham and Women's Hospital provides additional clinical support for KynderMed's core developmental technology focused on reducing preterm birth.

KynderMed, Inc. (<https://www.KynderMed.com>) is a development stage company pursuing a unique approach to reducing the incidence of preterm birth through the use of a propriety technology embodied in a non-invasive medical device using very low intensity light to suppress the secretion of the hormone melatonin which in turn reduces spontaneous contractions.

The Harvard study recently published in the Journal of Pineal Research, reaffirmed that "agents that change melatonin levels (light) may be used to modulate uterine contractions." The study went on to state that "if uterine melatonin receptors are expressed and/or activated during pregnancy, they may provide a key hormonal event in the initiation of labor: blocking these receptors may be an effective treatment in preterm or late-term labor." The study was conducted by researchers at Harvard Medical School, Brigham and Women's Hospital and Florida State University's College of Medicine.

Marc Lawrence, President of KynderMed, said that "the NIH-funded Harvard study adds to our body of human clinical evidence that we can employ our propriety light-based technology to suppress contractions in preterm pregnancies. An additional clinical trial is currently underway. We hope to be able to provide a solution to reduce the tragedies associated with preterm birth . . . globally over 1,000,000 infants die each year and another 2,000,000 are born with severe lifelong disabilities. Currently there are no safe and effective means of addressing this tremendously unmet medical need."

KynderMed's core technology was developed by James Olcese, PhD, a Professor at Florida State University's College of Medicine and noted authority in melatonin and circadian rhythms. KynderMed acquired exclusive rights to his science from the University.

Newport, LLC is providing advisory and board services to the Company.

Contact Information:

Name: Marc Lawrence, President and CEO

Email: marc.lawrence(at)kyndermed(dot)com

Address: 9800 4th Street N, Suite 200, St. Petersburg, Fla. 33702

Telephone: (440) 225-5330

SOURCE KynderMed, Inc.

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

SEE ALSO: Lyft is having a messy first few days of trading (LYFT)